Prostate & Breast Cancer- New Treatments & Developmental Progres

Table of Contents

1 Executive Summary

2 Methodology

3 Table of Contents

• 3.1 List of Boxes
• 3.2 List of Tables

4 Prostate Cancer

• 4.1.1 Introduction
• 4.1.2 Disease Definitions
• 4.1.3 Etiology & Pathophysiology
• 4.1.4 Epidemiology
• 4.1.5 Prognosis
• 4.2 Current Treatment Strategies
  • 4.2.1 Localized Disease
    • 4.2.1.1 Locally Advanced Prostate Cancer
  • 4.2.2 Metastatic Prostate Cancer
    • 4.2.2.1 Hormone-Sensitive Metastatic Prostate Cancer
    • 4.2.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer
• 4.3 Progress in Current Treatment Strategies
  • 4.3.1 Hormone Modulators
  • 4.3.2 Chemotherapy
• 4.4 Key Therapeutic Strategies for Future Therapies
  • 4.4.1 Therapeutic Type, Targets & Mechanisms
• 4.5 Competitive Landscape in Drug Development: The Late Stage Pipeline
  • 4.5.1 Hormone Modulators
  • 4.5.2 Protein Kinase Inhibitors
  • 4.5.3 Apoptotic Inducers
  • 4.5.4 Immunotherapy
  • 4.5.5 DNA Binding
  • 4.5.6 Other
• 4.6 Current Drug Development: The Early Stage Pipeline
  • 4.6.1 Epothilones
  • 4.6.2 Protein Kinse Inhibitors
  • 4.6.3 Other
  • 4.6.4 Chemotherapy

5 Breast Cancer

• 5.1 Introduction
  • 5.1.1 Disease Definitions
  • 5.1.2 Etiology
  • 5.1.3 Epidemiology
  • 5.1.4 Prognosis
• 5.2 Current Treatment Strategies
  • 5.2.1 Localized Disease
  • 5.2.2 Advanced Disease
• 5.3 Progress in Current Treatment Strategies
  • 5.3.1 Hormone Based Therapies
  • 5.3.2 Antibodies
  • 5.3.3 Chemotherapy
• 5.4 Key Therapeutic Strategies for Future Therapies
  • 5.4.1 Therapeutic Type, Targets & Mechanisms
• 5.5 Competitive Landscape in Drug Development: The Late Stage Pipeline
  • 5.5.1 The Epothilones
  • 5.5.2 Cell Cycle & Apoptosis
  • 5.5.3 Protein Kinase Inhibitors
  • 5.5.4 Immunotherapy
• 5.6 Current Drug Development: The Early Stage Pipeline
  • 5.6.1 DNA Targeting
  • 5.6.2 FTIs
  • 5.6.3 Antisense
  • 5.6.4 New Hormone Modulators
  • 5.6.5 Other
• 5.7 Disclaimer
  • 5.7.1 Liability
  • 5.7.2 Completeness

6 Drug Index

7 Company Index

List of Boxes

• Box 1: The Eastern Cooperative Oncology Group Study
• Box 2: Southwest Oncology Group Study 99-16 Design
• Box 3: TAX 327 Study Design
• Box 4: Quick Facts - Toremifene
• Box 5: Quick Facts - Bevacizumab
• Box 6: Quick Facts - Genasense
• Box 7: Quick Facts - R-flurbiprofen
• Box 8: Quick Facts - Exisulind
• Box 9: Quick Facts - Provenge
• Box 10: Quick Facts - GVAX
• Box 11: Quick Facts - Satraplatin
• Box 12: Quick Facts - Vapreotide
• Box 13: Quick Facts - DCVax
• Box 14: Ongoing Phase III Studies Anastrozole
• Box 15: Ongoing Phase III Studies Letrozole
• Box 16: Ongoing Phase III Studies Exemestane
• Box 17: Ongoing Phase III Studies Goserelin
• Box 18: Ongoing Phase III Studies Fulvestrant
• Box 19: Ongoing Phase III Studies Trastuzumab
• Box 20: Quick Facts - BMS-247550
• Box 21: Quick Facts - Temsirolimus
• Box 22: Quick Facts - SDX-105
• Box 23: Quick Facts - 4HPR
• Box 24: Quick Facts - Lapatinib
• Box 25: Quick Facts - Bevacizumab
• Box 26: Quick Facts - Theratope
• Box 27: Erlotinib
• Box 28: Gefitinib
• Box 29: Imatinib
• Box 30: Pemetrexed
• Box 31: NX473
• Box 32: Lonafarnib
• Box 33: Tipifarnib
• Box 34: Bortezomib
• Box 35: Arzoxifene
• Box 36: Patupilone
• Box 37: KOS-862

List of Tables

• Table 1: The TNM System
• Table 2: Lifestyle factors
• Table 3: Historical Summary of Clinical Studies on Patients with Late Stage Disease
• Table 4: Short Facts Bicalutamide
• Table 5: Short Facts Flutamide
• Table 6: Short Facts Goserelin
• Table 7: Short Facts Histrelin
• Table 8: Short Facts Lanreotide
• Table 9: Short Facts Leuprolide
• Table 10: Short Facts Nilutamide
• Table 11: Short Facts Abarelix
• Table 12: Short Facts Mitoxantrone
• Table 13: Short Facts Carboplatin
• Table 14: Short Facts Docetaxel
• Table 15: Short Facts Estramustine
• Table 16: Summary of Recent Clinical Studies on Patients with Late Stage Disease
• Table 17: Ongoing Late Stage Clinical Studies
• Table 18: Cancer Immunotherapy Strategies
• Table 19: Near Term Progress Toremifene
• Table 20: Near Term Progress Bevacizumab
• Table 21: Near Term Progress Oblimersen
• Table 22: Near Term Progress R-flurbiprofen
• Table 23: Near Term Progress Exisulind
• Table 24: Near Term Progress APC8015
• Table 25: Near Term Progress GVAX
• Table 26: Near Term Progress Satraplatin
• Table 27: Summary of Prostate Cancer Late Stage Pipeline
• Table 28: Epothilone
• Table 29: Ixabepilone
• Table 30: PTK/ZK
• Table 31: Imatinib
• Table 32: Bortezomib
• Table 33: Sorafenib
• Table 34: Arsenic trioxide
• Table 35: Retinoic Acid
• Table 36: Paclitaxel
• Table 37: Doxorubicin
• Table 38: Summary of Prostate Cancer Early Stage Pipeline
• Table 39: The Stage System
• Table 40: Risk Factors
• Table 41: List of Approved Drugs and Their Mechanisms of Action.
• Table 42: Hormonal Treatment Strategies
• Table 43: Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative Breast Cancer
• Table 44: Treatment Options for Women With Axillary Node-Positive Breast Cancer
• Table 45: Chemotherapy Drugs and Regimen
• Table 46: Summay of Drugs Involved in Breast Cancer Therapy
• Table 47: Short Facts Tamoxifen
• Table 48: Short Facts Anastrozole
• Table 49: Short Facts Letrozole
• Table 50: Short Facts Exemestane
• Table 51: Short Facts Goserelin
• Table 52: Short Facts Fulvestrant
• Table 53: Short Facts Trastuzumab
• Table 54: Cancer Immunotherapy Strategies
• Table 55: Progress on Ixabepilone
• Table 56: Progress on CCI-779
• Table 57: Progress on Fenretinide
• Table 58: Progress on Lapatinib
• Table 59: Progress on Bevacizumab
• Table 60: Progress on Theratope
• Table 61: Summary of Mid-Stage to Late stage Investigational Agents Under Development
• Table 62: Summary of Breast Cancer Early Stage Pipeline